Premium
Daily Mango ( Mangifera Indica L. ) Consumption for 42 Days Differentially Modulates Metabolism and Inflammation in Lean and Obese Individuals
Author(s) -
Fang Chuo,
Kim Hyemee,
Barnes Ryan,
Talcott Stephen T,
MertensTalcott Susanne U
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.431.3
Subject(s) - medicine , obesity , diabetes mellitus , mangifera , overweight , metabolic syndrome , inflammation , endocrinology , physiology , biology , botany
Excess weight and body fat increase the risk of developing multiple medical conditions, including Type 2 Diabetes, cardiovascular diseases, and cancer, which pose major threats to public health. Diets rich in fruits and vegetables have been recommended for preventing metabolic disorder and cardiovascular disease. Mangoes are reported to have high concentrations of polyphenols that exert potent anti‐inflammatory activities relevant to the treatment of chronic diseases and cancer, as demonstrated in preclinical studies. However, the number of human clinical trials examining the metabolic effects of mango polyphenols is limited. This study was carried out to investigate the effects of daily mango consumption for 42 days in lean and obese individuals. In this study, 21 healthy lean (BMI 18–25kg/m 2 ) and obese (BMI>30kg/m 2 ) subjects aged 18–55, were continuously provided with 400g of mango pulp for 42 days. Inflammatory cytokines, metabolic hormones, and lipid profiles were examined in plasma at a baseline and after 42 days of treatment. A three‐day food record was filled out for dietary assessment prior to each clinical visit. Results revealed that 42 days of mango consumption decreased systolic blood pressure (mean ± SD: 119.83±13.16 vs. 115.42±12.33; p<0.05) in lean subjects, but had no significant effect in obese subjects. The level of hemoglobin A1c was improved significantly in obese but not lean subjects. Reduced expression of PAI‐1, associated with reduced risk of atherosclerosis and thrombosis, was observed in both groups (In lean group, mean ± SD: 30.93±18.12 vs. 23.69±17.58; p<0.1; In obese group, mean ± SD: 31.34±8.09 vs. 24.93±12.20; p<0.05). There was a non‐significant trend towards lowered levels of C‐reactive protein, and elevated levels of IL‐10 in both groups. No significant changes were observed in lipid profiles for either group. The consumption of mango did not improve the plasma levels of adipokines. In conclusion, daily mango consumption lowers blood pressure in lean individuals, and benefits obese individuals by maintaining long‐term glucose homeostasis. Galloyl‐derivatives from mango may possess therapeutic potential in the prevention and treatment of obesity and metabolic disorders, which remain to be confirmed in a larger‐size human clinical trial. Support or Funding Information Partial funding for this research was provided by: National Mango Board